Healthcare & Life Sciences
FlowMedica
United States
acquiredacquired
acquired
Stage
1
Investors
About
FlowMedica developed proprietary, minimally invasive intravascular infusion systems to deliver targeted renal therapy as an alternative to systemic intravenous infusion, addressing kidney dysfunction caused by various diseases. The company's assets were sold to AngioDynamics in 2009.
Explore FlowMedica's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.